{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:19:59Z","timestamp":1784762399205,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40256-022-00557-2","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T16:03:02Z","timestamp":1673539382000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct03504982","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael","family":"B\u00f6ttcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dirk","family":"D\u00fcngen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile","family":"Corcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Donath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainard","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Vieira","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios Othon","family":"Aliprantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Besche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-6726","authenticated-orcid":false,"given":"Corina","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"557_CR1","unstructured":"US Food and Drug Administration. VERQUVOTM (vericiguat) tablets. Highlights of prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214377s000lbl.pdf. Accessed 11 May 2022."},{"key":"557_CR2","unstructured":"Bayer plc. Verquvo 10 mg film-coated tablets SmPC. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/12775\/smpc#gref. Accessed 27 Aug 2021."},{"issue":"36","key":"557_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"20","key":"557_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"key":"557_CR5","unstructured":"European Medicines Agency. ICH topic E14. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluation-qt\/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf. Accessed 11 May 2021."},{"issue":"12","key":"557_CR6","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","volume":"29","author":"KE Trinkley","year":"2013","unstructured":"Trinkley KE, Page RL, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719\u201326.","journal-title":"Curr Med Res Opin"},{"issue":"77","key":"557_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","volume":"2021","author":"M Boettcher","year":"2021","unstructured":"Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;2021(77):527\u201337.","journal-title":"Eur J Clin Pharmacol"},{"key":"557_CR8","unstructured":"US Food and Drug Administration. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers (R3) guidance for industry. 2017. https:\/\/www.fda.gov\/media\/71379\/download. Accessed 11 May 2021."},{"issue":"3","key":"557_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"key":"557_CR10","unstructured":"US Food and Drug Administration. AVELOX (moxifloxacin hydrochloride) prescribing information. 1999. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021085s063lbl.pdf. Accessed 26 Mar 2021."},{"key":"557_CR11","doi-asserted-by":"crossref","unstructured":"Meyer M, Ruehs H, Solms A, Frei M, Becker C, Trujillo M, et al. A concentration-QTc analysis of vericiguat. European Society of Cardiology Congress; Aug 27\u201330, 2021.","DOI":"10.1093\/eurheartj\/ehab724.0910"},{"issue":"1","key":"557_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bcp.12168","volume":"77","author":"J Taubel","year":"2014","unstructured":"Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2014;77(1):170\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"557_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10928-012-9242-8","volume":"39","author":"P Grosjean","year":"2012","unstructured":"Grosjean P, Urien S. Moxifloxacin versus placebo modeling of the QT interval. J Pharmacokinet Pharmacodyn. 2012;39(2):205\u201315.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"557_CR14","unstructured":"CredibleMeds. Clinical factors associated with prolonged QTc and\/or TdP. https:\/\/www.crediblemeds.org\/ndfa_list. Accessed 9 Jul 2021."},{"key":"557_CR15","doi-asserted-by":"crossref","unstructured":"Himmel H, Lagrutta A, Voemel M, Amin R, Imredy J, Johnson T, et al. Lack of pro-arrhythmic potential for the novel soluble guanylate cyclase stimulator vericiguat: results from preclinical studies. European Society of Cardiology Congress; Aug 27\u201330, 2021.","DOI":"10.1093\/eurheartj\/ehab724.0921"},{"issue":"15","key":"557_CR16","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Lam C, Anstrom K, Ezekowitz J, Hernandez A, O\u2019Connor C, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512\u201321.","journal-title":"JAMA"},{"issue":"3","key":"557_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13300-011-0003-2","volume":"2","author":"GF Carlson","year":"2011","unstructured":"Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT\/QTc study. Diabetes Ther. 2011;2(3):123\u201332.","journal-title":"Diabetes Ther."},{"issue":"12","key":"557_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1475-2840-12-70","volume":"24","author":"A Ring","year":"2013","unstructured":"Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013;24(12):70.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"557_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00228-016-2062-9","volume":"72","author":"TH Langenickel","year":"2016","unstructured":"Langenickel TH, Jordaan P, Petruck J, Kode K, Pal P, Vaidya S, et al. Single therapeutic and supratherapeutic doses of sacubitril\/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016;72(8):917\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"557_CR20","unstructured":"US Food and Drug Administration. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees. 2006. https:\/\/www.fda.gov\/media\/75398\/download. Accessed 18 Oct 2022."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00557-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00557-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:36:38Z","timestamp":1678462598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00557-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00557-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"10 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Corina Becker and Claudia Maschke are employees of Bayer AG. Philippe Vieira Pires was previously an employee of Bayer AG at the time of the study.\u00a0Michael B\u00f6ttcher is a former employee of Bayer AG, and has received within the last 36 months, salary, pension, and payment for writing and reviewing vericiguat manuscripts from Bayer AG and for lectures, exercises, and awarding and supporting bachelor and master theses. Dietmar Trenk received within the last 36 months through to the foreseeable future consulting fees\/payment for lectures including service on speakers\u2019 bureaus by Amgen, AstraZeneca, Atriva, Bayer, Berlin Chemie, Bristol-Myers Squibb, B\u00f6hringer Ingelheim, Daiichi Sankyo, Ferrer, Pfizer, and Sanofi. Hans-Dirk D\u00fcngen has received institutional payment as an investigator and personal honoraria for advisory boards from Bayer. Antonios Othon\u00a0Aliprantis was an employee of Merck & Co., Inc., Rahway, NJ, USA, at the time the study was conducted and held stock in the company. Rainard Fuhr is an employee of Parexel, the Clinical Research Organization that received funding from Bayer AG for the conduct of the study. Nina Besche is an employee of Chrestos Concept GmbH & Co. KG, which received funding for this analysis from Bayer AG. Martin Coenen received travel costs from Bayer AG to attend an investigator meeting related to the conduct of the study. Frank Donath, Pim Gal, Gerd Mikus, and Vasile Corcea declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the ICH guideline E6: Good Clinical Practice and met all local legal and regulatory requirements. During the study, all clinical data were monitored by an independent data monitoring committee [].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before any study procedure was performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}